MRD and ctDNA move toward clinic: Exact Sciences, Natera push trials and coverage

Exact Sciences presented first data showing its Oncodetect MRD test stratified distant‑recurrence risk in triple‑negative breast cancer in an NSABP B‑59 sub‑study; MRD‑positive patients after surgery had a materially higher risk of distant recurrence. Exact plans to publish full results and submit data to MolDx for Medicare coverage consideration. Separately, Natera launched a collaboration with MEDSIR on the MiRaDoR trial, using Signatera Genome to enroll HR+/HER2‑ early breast cancer patients with MRD‑positive ctDNA and to test targeted adjuvant strategies. Both moves highlight continued industry momentum to use ctDNA MRD as a tool for adjuvant decision‑making and payer engagement.